
|Videos|July 29, 2021
Dr. Helfand on how genomic testing provides real-time status of prostate tumor
Author(s)Urology Times staff
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”
Advertisement
Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to Enolen for localized prostate cancer
2
Pivotal trial of Butterfly Device for BPH reaches final completion
3
Trial to assess testosterone undecanoate in older men with hypogonadism
4
Genomic classifier score linked with focal therapy outcomes in prostate cancer
5




















